Table 1

Included studies.

METHODS

PARTICIPANTS

INTERVENTIONS

OUTCOMES


INCLUDED STUDIES (date of publication)

Randomised

Double-blind

Three+ arm study

Duration (weeks)

Only Schizophrenia

History

Total number of participants

Age (years)

Sex

CPZ dose (mg/day)

Number allocated CPZ

Number allocated placebo

Leaving the study early

Global improvement

Mental State

Side-effects

Global clinical state

Behaviour

Relapse


1955

Hall

9

C

175

20–59

M+F

750 max

87

88

Vaughan

U/K

C

48

M = 43

F

75–450

24

24

1956

Shepherd

U/K

6

C

24

27–52

F

300

8

8

1958

Abrams

4

C

40

20–55

F

200–600

20

20

Grygier

U/K

24

C

30

m = 50

F

150

15

15

Hine

20

C

22

30–50

F

750 max

11

11

Simon

4

U/K

80

m = 31

U/K

200–1200

20

0

1959

Baker

5

C

25

33–79

F

150–300

7

7

Flemming

26

C

63

m = 58

F

75–300

21

21

Walsh

U/K

8

C

66

27–50

F

75–300

22

22

1960

Englhardt

78

U/K

173

18–40

U/K

50–800

62

56

Hamilton

8

C

54

m = 38

M

300

18

18

Payne

6

C

21

23–73

M

25–100

7

7

Somerville

6

C+A

60

24–58

F

200–800

15

30

1961

Clark

24

C

60

26–52

F

200–800

20

20

Lorr

12

A

308

<50

M

50–100

63

61

Kurland

6

A

277

18–61

M+F

300

33

72

Schiele

16

C

80

m = 80

M

200–1000

20

20

Smith

14

C

30

m = 42

M+F

150–600

13

15

1963

Bishop

10

C

30

U/N

M+F

800

10

10

Fink

U/K

6

S

311

m = 31

M+F

1200

51

44

1964

NIMH

6

A

463

16–45

M+F

200–1600

112

125

1966

Reardon

4

A

34

U/K

M+F

300–600

11

12

Saretsky

12

A

40

<55

M

400

20

20

1967

Clark

10

C

72

25–55

F

678 m

51

21

Letemendia

39

C

28

<65

M

300

14

14

1968

Clark a

14

C

72

20–60

F

1000 max

18

36

Clark b

16

C

69

20–60

F

1000 max

23

23

Cohen

60

C

126

18–42

M+F

180

42

42

Prien

24

C

838

19–55

M+F

2000

208

212

300

208

1969

Tetreault

12

C

45

m = 50

F

300–600

15

15

1970

Clark a

12

C

44

22–55

M+F

200–1000

15

14

Clark b

24

C

71

21–60

F

150–600

54

18

1971

Clark

4

C

86

21–45

M+F

200–1000

23

21

1972

Clark

12

C

55

21–60

M+F

1000

19

18

Serafetinedes

12

C

57

21–61

M+F

1000 max

14

13

1973

Hogarty

156

S

374

18–53

M+F

270 m

192

182

Klein

6

88

17–61

M+F

300–1200

46

42

1974

Reschke

0.1

A

50

19–57

M+F

25 im

10

11

1975

Ban

12

C+A

30

17–46

M+F

200–800

10

10

Hamill

0.7

A

44

18–55

M+F

306–475

22

22

1977

Clark

12

C

27

23–61

M+F

1000

9

9

Spohn

6+

U/K

40

18–55

M+F

200 min

20

20

1978

Rappaport

U/K

A

127

16–40

M

300–900

53

74

1981

Peet

12

U/K

53

m = 51

M+F

400 max

16

18

1982

Nishikawa

156

S

55

m = 33

M+F

75

10

10

1986

Zuoze

4

C

60

m = 36

U/K

450 m

20

20

1990

Chouinard

4

A

62

19–62

M+F

300–1200

21

21

1991

Borison

4

A

30

22–58

M

400–1600

9

10

2000

Cooper

8

C

159

18–42

M+F

600

53

53


Key: ● = Yes; U/K = Unknown; C = Chronic; A = Acute; M = Male; F = Female; m = Mean; im = Intramuscular injection.

Adams et al. BMC Medicine 2005 3:15   doi:10.1186/1741-7015-3-15

Open Data